Hepion Pharmaceuticals (HEPA) executive compensation, 2026 proxy

Kaouthar Lbiati, M.D., Former Chief Executive Officer, was paid $198,021 in 2025.

Filed
April 28, 2026
Annual meeting
June 17, 2026
Pay year
2025
Named executives
2
CEO total pay
$198,0212025
Proposed Plan Shares
8,000,000Increase from 200,000 shares
Basic Shares Outstanding
29,119,317As of April 28, 2026
Fully-Diluted Shares
32,604,038As of April 28, 2026

How M.D. was paid

$198,021 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary100%

Named executive officers

ExecutiveTotal
John BrancaccioFormer Interim Chief Executive Officer and Chief Financial Officer$232,500
Kaouthar Lbiati, M.D.Former Chief Executive Officer$198,021

What changed and why

  • $198KKaouthar Lbiati received total compensation of $198,021 as former Chief Executive Officer for fiscal 2025.
  • $233KJohn Brancaccio received total compensation of $232,500 for his service as former Interim Chief Executive Officer and Chief Financial Officer in fiscal 2025.
  • The company is proposing an amendment to the 2023 Omnibus Equity Incentive Plan to increase shares issuable to 8,000,000 from 200,000.
  • Executive leadership underwent several changes with both John Brancaccio and Kaouthar Lbiati resigning from their respective executive roles.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.